Becton Dickinson EBITDA 2010-2024 | BDX
Becton Dickinson annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Becton Dickinson EBITDA for the quarter ending September 30, 2024 was $1.210B, a 29% increase year-over-year.
- Becton Dickinson EBITDA for the twelve months ending September 30, 2024 was $4.684B, a 6.48% increase year-over-year.
- Becton Dickinson 2024 annual EBITDA was $4.684B, a 6.48% increase from 2023.
- Becton Dickinson 2023 annual EBITDA was $4.399B, a 2.5% decline from 2022.
- Becton Dickinson 2022 annual EBITDA was $4.512B, a 0.69% increase from 2021.
Becton Dickinson Annual EBITDA
(Millions of US $) |
| 2024 |
$4,684 |
| 2023 |
$4,399 |
| 2022 |
$4,512 |
| 2021 |
$4,481 |
| 2020 |
$3,027 |
| 2019 |
$4,013 |
| 2018 |
$3,487 |
| 2017 |
$2,610 |
| 2016 |
$2,544 |
| 2015 |
$1,965 |
| 2014 |
$2,168 |
| 2013 |
$1,801 |
| 2012 |
$2,069 |
| 2011 |
$2,159 |
| 2010 |
$2,074 |
| 2009 |
$2,054 |
Becton Dickinson Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$1,210 |
| 2024-06-30 |
$1,170 |
| 2024-03-31 |
$1,305 |
| 2023-12-31 |
$999 |
| 2023-09-30 |
$938 |
| 2023-06-30 |
$1,118 |
| 2023-03-31 |
$1,190 |
| 2022-12-31 |
$1,153 |
| 2022-09-30 |
$1,070 |
| 2022-06-30 |
$1,091 |
| 2022-03-31 |
$1,114 |
| 2021-12-31 |
$1,237 |
| 2021-09-30 |
$666 |
| 2021-06-30 |
$1,027 |
| 2021-03-31 |
$991 |
| 2020-12-31 |
$1,797 |
| 2020-09-30 |
$197 |
| 2020-06-30 |
$893 |
| 2020-03-31 |
$906 |
| 2019-12-31 |
$1,031 |
| 2019-09-30 |
$665 |
| 2019-06-30 |
$1,200 |
| 2019-03-31 |
$699 |
| 2018-12-31 |
$1,449 |
| 2018-09-30 |
$1,142 |
| 2018-06-30 |
$1,079 |
| 2018-03-31 |
$740 |
| 2017-12-31 |
$526 |
| 2017-09-30 |
$777 |
| 2017-06-30 |
$55 |
| 2017-03-31 |
$706 |
| 2016-12-31 |
$1,072 |
| 2016-09-30 |
$370 |
| 2016-06-30 |
$788 |
| 2016-03-31 |
$745 |
| 2015-12-31 |
$641 |
| 2015-09-30 |
$610 |
| 2015-06-30 |
$436 |
| 2015-03-31 |
$431 |
| 2014-12-31 |
$488 |
| 2014-09-30 |
$550 |
| 2014-06-30 |
$587 |
| 2014-03-31 |
$511 |
| 2013-12-31 |
$520 |
| 2013-09-30 |
$219 |
| 2013-06-30 |
$544 |
| 2013-03-31 |
$517 |
| 2012-12-31 |
$521 |
| 2012-09-30 |
$516 |
| 2012-06-30 |
$572 |
| 2012-03-31 |
$511 |
| 2011-12-31 |
$470 |
| 2011-09-30 |
$494 |
| 2011-06-30 |
$567 |
| 2011-03-31 |
$563 |
| 2010-12-31 |
$536 |
| 2010-09-30 |
$429 |
| 2010-06-30 |
$553 |
| 2010-03-31 |
$539 |
| 2009-12-31 |
$553 |
| 2009-09-30 |
$491 |
| 2009-06-30 |
$550 |
| 2009-03-31 |
$478 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$64.714B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
